PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739755
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Nomogram Model of LNR Predicts Survival in Premenopausal Patients with
      Node-positive Luminal Breast Cancer.
PG  - 4575-4586
AB  - AIM: The aim of this study was to assess the prognostic value of lymph node ratio
      (LNR) in premenopausal patients with luminal breast carcinoma. MATERIALS AND
      METHODS: A total of 885 female patients who presented with axillary lymph
      node-positive luminal breast cancer between 2000 and 2009 were investigated.
      Using X-tile, we classified patients into low-, intermediate- and high-risk
      groups based on LNR. The Kaplan-Meier method was used to determine cumulative
      survival curves. Cox proportional hazards analyses were used to identify the
      factors that contributed to disease-free (DFS) and overall (OS) survival.
      RESULTS: The median age of patients was 42 years (range=21-58 years). A training 
      set of 295 patients and a validation set of 590 patients were used to determine
      the optimal LNR cut-off points (0.20 and 0.63). DFS was 87.7%, 77.4% and 53.9%
      (p<0.001) and OS was 91.5%, 76.7% and 50.9% (p<0.0001) for the low- (</=0.20),
      intermediate- (0.21-0.63) and high-risk (>0.63) groups, respectively. The 10-year
      DFS and OS rates were significantly longer in the low-risk group than in the
      high-risk group. Nomogram analysis demonstrated that LNR contributed more
      compared to nodal stage in predicting both DFS and OS. CONCLUSION: We conclude
      that LNR strongly predicts prognosis in premenopausal patients with lymph
      node-positive luminal breast cancer.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Qin, Tao
AU  - Qin T
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
AD  - Breast Tumor Center, Sun Yat-sen University Sun Yat-sen Memorial Hospital,
      Guangzhou, P.R. China.
FAU - Zeng, Yin-Duo
AU  - Zeng YD
AD  - Breast Tumor Center, Sun Yat-sen University Sun Yat-sen Memorial Hospital,
      Guangzhou, P.R. China.
FAU - Lu, Qianyi
AU  - Lu Q
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Zhang, Xinke
AU  - Zhang X
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Qin, G E
AU  - Qin GE
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Zheng, Qiufan
AU  - Zheng Q
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Xu, Fei
AU  - Xu F
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Peng, Roujun
AU  - Peng R
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China.
FAU - Yuan, Zhongyu
AU  - Yuan Z
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China [email protected]
      [email protected]
FAU - Wang, Shusen
AU  - Wang S
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State
      Key Laboratory of Oncology in South China, Collaborative Innovation Center for
      Cancer Medicine, Guangzhou, P.R. China [email protected]
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*mortality/*pathology/therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Nomograms
MH  - *Premenopause
MH  - Prognosis
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Lymph node ratio
OT  - breast cancer
OT  - luminal subtype
OT  - nomogram
OT  - prognosis
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/12 [received]
PHST- 2017/06/09 [revised]
PHST- 2017/06/16 [accepted]
AID - 37/8/4575 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4575-4586.